Search This Blog

Thursday, May 4, 2023

Sandoz to exclusively commercialize 6 products in the US, reinforcing lead in off-patent medicines

 

  • Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology.

  • Products from Adalvo slated for near- to mid-term launches, with four out of six anticipated to be first-to-market

  • Sandoz continues to expand patient access to much-needed medications, drive patient savings, and ensure the sustainability of healthcare systems worldwide

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.